Common use of Tail Clause in Contracts

Tail. In the event, and only in the event, an Offering is not completed during the Term, W▇▇▇▇▇▇▇▇▇ shall be entitled to compensation under clauses (1) and (2) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (“Tail Financing”) to the extent that such financing or capital is provided to the Company by investors whom W▇▇▇▇▇▇▇▇▇ had contacted during the Term or introduced to the Company during the Term, if such Tail Financing is consummated at any time within the 12-month period following the expiration or termination of this Agreement.

Appears in 2 contracts

Sources: Exclusive Agency Agreement (Bio-Path Holdings Inc), Exclusive Agency Agreement (Bio-Path Holdings Inc)

Tail. In the event, and only in the event, an Offering is not completed Provided a Closing occurs during the Term, W▇▇▇▇▇▇▇▇▇ shall be entitled to compensation under clauses (1) and (2) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (“Tail Financing”) to the extent that such financing or capital is provided to the Company by (a) investors whom W▇▇▇▇▇▇▇▇▇ had contacted introduced to the Company during the Term or introduced to (b) investors with whom the Company had an in-person meeting or a call during the Term, if such Tail Financing is consummated at any time within the 12-month period following the expiration or termination of this Agreement.

Appears in 2 contracts

Sources: Exclusive Agency Agreement (Citius Pharmaceuticals, Inc.), Exclusive Agency Agreement (Citius Pharmaceuticals, Inc.)

Tail. In the event, and only in the event, event an Offering is does not completed close during the Term, W▇▇▇▇▇▇▇▇▇ shall be entitled to compensation under clauses (1) and (2) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (“Tail Financing”) to the extent that such financing or capital is provided to the Company by investors whom W▇▇▇▇▇▇▇▇▇ had contacted during the Term or introduced to the Company during the Term, if such Tail Financing is consummated at any time within the 12-month period following the expiration or termination of this Agreement.

Appears in 1 contract

Sources: Exclusive Agency Agreement (Eyegate Pharmaceuticals Inc)

Tail. In the event, and only in the event, event an Offering is does not completed close during the Term, W▇▇▇▇R▇▇▇▇▇ shall be entitled to compensation under clauses (1) and (2) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (“Tail Financing”) to the extent that such financing or capital is provided to the Company by investors whom W▇▇▇▇R▇▇▇▇▇ had contacted during the Term or introduced to the Company during the Term, if such Tail Financing is consummated at any time within the 12six-month period following the expiration or termination of this Agreement.

Appears in 1 contract

Sources: Exclusive Agency Agreement (Eyegate Pharmaceuticals Inc)

Tail. In the event, and only in the event, an Offering is not completed during the Term, W▇▇▇▇▇▇▇▇▇ shall be entitled to compensation under clauses (1) and (2) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (“Tail Financing”) to the extent that such financing or capital is provided to the Company by investors whom W▇▇▇▇▇▇▇▇▇ had contacted during the Term or introduced to the Company during the Term, if such Tail Financing is consummated at any time within the 127-month period following the expiration or termination of this Agreement.

Appears in 1 contract

Sources: Exclusive Agency Agreement (Bio-Path Holdings Inc)

Tail. In the event, and only in the event, event an Offering is does not completed close during the Term, W▇▇▇▇▇▇▇▇▇ shall be entitled to compensation under clauses clause (1) and (2) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (“Tail Financing”) to the extent that such financing or capital is provided to the Company by investors whom W▇▇▇▇▇▇▇▇▇ had contacted during the Term or introduced to the Company during the Term, if such Tail Financing is consummated at any time within the 126-month period following the expiration or termination of this Agreement.

Appears in 1 contract

Sources: Exclusive Agency Agreement (Eyegate Pharmaceuticals Inc)